The expression of miRNA-216b is negatively correlated with 18F-FDG uptake in non-small cell lung cancer
Tóm tắt
This study aimed to investigate the correlation between miRNA-216b expression in patients with non-small cell lung cancer (NSCLC) and 18F-fluorodeoxyglucose (FDG) uptake by PET/CT and to explore the clinical application value of 18F-FDG PET/CT in miRNA-216b based on therapy for NSCLC.
Eighty patients with NSCLC and 40 healthy subjects were enrolled in our study. The SUVmax of the lesion area by PET/CT imaging was calculated. SUVmax represented the highest concentration of 18F-FDG in the lesion. The expression of miRNA-216b in the plasma and fiber bronchoscopic puncture of NSCLC patients was detected by RT qPCR. Then Pearson correlation analysis was used to analyze the correlation between miRNA-216b expression and 18F-FDG uptake in patients with different types of NSCLC.
Compared with healthy subjects, SUVmax of early adenocarcinoma and advanced adenocarcinoma were increased. Compared with healthy subjects, SUVmax of early squamous and advanced squamous were increased. And the SUVmax content of advanced adenocarcinoma and squamous cell carcinoma was higher than that of early adenocarcinoma and squamous cell carcinoma. Compared with healthy subjects, the expression of miRNA-216b in the plasma of patients with early and advanced adenocarcinoma was reduced, and the expression of miRNA-216b in the plasma of patients with early and advanced squamous cell carcinoma was reduced. Compared with adjacent tissues, the expression of miRNA-216b in early adenocarcinoma tissues and advanced adenocarcinoma tissues was reduced, and the expression in early squamous cell carcinoma and advanced squamous cell carcinoma was reduced. Pearson correlation analysis showed a negative correlation between SUVmax and miRNA-216b (plasma and tissue) in patients with four types of NSCLC.
miRNA-216b expression was negatively correlated with 18F-FDG uptake in NSCLC. miRNA-216b could be used for the classification and staging of non-small cell lung cancer. 18F-FDG PET/CT may be used to evaluate the therapeutic response in application of miRNA-216b-based cancer treatment.
Từ khóa
Tài liệu tham khảo
Theegarten D, Hager T. Pathology of lung cancer. Radiologe. 2016;56(9):777–85. https://doi.org/10.1007/s00117-016-0154-2.
Castro-Pocas FM, Araújo TP, Ferreira ML, et al. The role of endoscopic ultrasound in a case of lung cancer with jaundice. Endosc Ultrasound. 2018;7(4):279–81. https://doi.org/10.4103/2303-9027.193570.
Cazacu IM, Luzuriaga Chavez AA, Saftoiu A, Vilmann P, Bhutani MS. A quarter century of EUS-FNA: progress, milestones, and future directions. Endosc Ultrasound. 2018;7(3):141–60. https://doi.org/10.4103/eus.eus_19_18.
Yamane S, Katada C, Tanabe S, Azuma M, Ishido K, Yano T, et al. Clinical outcomes in patients with cancer of unknown primary site treated by gastrointestinal oncologists. J Transl Intern Med. 2017;5(1):58–63. https://doi.org/10.1515/jtim-2017-0006.
Montagnani F, Di Leonardo G, Pino M, et al. Protracted inhibition of vascular endothelial growth factor signaling improves survival in metastatic colorectal cancer: a systematic review. J Transl Intern Med. 2017;5(1):18–26. https://doi.org/10.1515/jtim-2017-0005.
Liu S, Dong H, Dai H, Liu D, Wang Z. MicroRNA-216b regulated proliferation and invasion of non-small cell lung cancer by targeting SOX9. Oncol Lett. 2018;15(6):10077–83. https://doi.org/10.3892/ol.2018.8573.
Robinson KW, Sandler AB. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist. 2013;18(2):115–22. https://doi.org/10.1634/theoncologist.2012-0262.
Greenspan BS. Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging. Transl Lung Cancer Res. 2017;6(6):617–20. https://doi.org/10.21037/tlcr.2017.09.01.
Wang K, Chen M, Wu W. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer. World J Surg Oncol. 2017;15(1):175. https://doi.org/10.1186/s12957-017-1244-y.
Xu L, Zheng Q. Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer. World J Surg Oncol. 2021;19(1):56. https://doi.org/10.1186/s12957-021-02137-1.
Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(01):3–11. https://doi.org/10.1055/s-0034-1397344.
Cai R, Lu Q, Wang D. Construction and prognostic analysis of miRNA-mRNA regulatory network in liver metastasis from colorectal cancer. World J Surg Oncol. 2021;19(1):7. https://doi.org/10.1186/s12957-020-02107-z.
Li X, Zhang Q, Jin X, Cao L. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules. World J Surg Oncol. 2017;15(1):107. https://doi.org/10.1186/s12957-017-1171-y.
Chen Y, Wei S, Wang X, Zhu X, Han S. Progress in research on the role of circular RNAs in lung cancer. World J Surg Oncol. 2018;16(1):215. https://doi.org/10.1186/s12957-018-1515-2.
Liang YY, Huang JC, Tang RX, Chen WJ, Chen P, Cen WL, et al. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR. World J Surg Oncol. 2018;16(1):22. https://doi.org/10.1186/s12957-018-1320-y.
Chen X, Liu X, He B, Pan Y, Sun H, Xu T, et al. MiR-216b functions as a tumor suppressor by targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal cancer. Am J Cancer Res. 2017;7(10):2051–69.
Zhan B, Lu D, Luo P, Wang B. Prognostic value of expression of microRNAs in non-small cell lung cancer: a systematic review and meta-analysis. Clin Lab. 2016;62(11):2203–11. https://doi.org/10.7754/Clin.Lab.2016.160426.
Miao Y, Zhang LF, Zhang M, Guo R, Liu MF, Li B. Therapeutic delivery of miR-143 targeting tumor metabolism in poorly differentiated thyroid cancer xenografts and efficacy evaluation using 18F-FDG microPET-CT. Hum Gene Ther. 2019;30(7):882–92. https://doi.org/10.1089/hum.2018.160.
Steendam CM, Dammeijer F, Aerts JGJV, et al. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. Immunotherapy. 2017;9(6):507–20. https://doi.org/10.2217/imt-2016-0151.
Hatt M, Tixier F, Pierce L, Kinahan PE, le Rest CC, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present... any future? Eur J Nucl Med Mol Imaging. 2017;44(1):151–65. https://doi.org/10.1007/s00259-016-3427-0.
Colleran GC, Kwatra N, Oberg L, Grant FD, Drubach L, Callahan MJ, et al. How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting. Cancer Imaging. 2017;17(1):28. https://doi.org/10.1186/s40644-017-0130-8.
Freebody J, Wegner EA, Rossleigh MA. 2-Deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology. World J Radiol. 2014;6(10):741–55. https://doi.org/10.4329/wjr.v6.i10.741.
Kluge R, Kurch L, Georgi T, Metzger M. Current role of FDG-PET in pediatric Hodgkin's lymphoma. Semin Nucl Med. 2017;47(3):242–57. https://doi.org/10.1053/j.semnuclmed.2017.01.001.
Kolinger GD, Vállez García D, Kramer GM, Frings V, Smit EF, de Langen AJ, et al. Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients. EJNMMI Res. 2019;9(1):14. https://doi.org/10.1186/s13550-019-0481-1.
Toma-Dasu I, Uhrdin J, Lazzeroni M, Carvalho S, van Elmpt W, Lambin P, et al. Evaluating tumor response of non-small cell lung cancer patients with 18F-fludeoxyglucose positron emission tomography: potential for treatment individualization. Int J Radiat Oncol Biol Phys. 2015;91(2):376–84. https://doi.org/10.1016/j.ijrobp.2014.10.012.
Frings V, van Velden FH, Velasquez LM, et al. Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 2014;273(2):539–48. https://doi.org/10.1148/radiol.14132807.
Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, et al. Repeatability of quantitative whole-body 18F-FDG PET/CT uptake measures as function of uptake interval and lesion selection in non-small cell lung cancer patients. J Nucl Med. 2016;57(9):1343–9. https://doi.org/10.2967/jnumed.115.170225.
Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, Spina CM, Wannesson L. MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. Curr Pharm Des. 2014;20(24):3982–90. https://doi.org/10.2174/13816128113196660755.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. https://doi.org/10.1016/S0092-8674(00)81683-9.
Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3(11):e3694. https://doi.org/10.1371/journal.pone.0003694.
Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Investig. 2011;91(4):579–87. https://doi.org/10.1038/labinvest.2010.194.
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28(10):1721–6. https://doi.org/10.1200/JCO.2009.24.9342.
Vannini I, Fanini F, Fabbri M. MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clin Biochem. 2013;46(10-11):918–25. https://doi.org/10.1016/j.clinbiochem.2013.01.024.
Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16(2):430–41. https://doi.org/10.1158/1078-0432.CCR-09-1736.
Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69(14):5776–83. https://doi.org/10.1158/0008-5472.CAN-09-0587.
Wang Y, Han R, Chen Z, et al. A transcriptional miRNA-gene network associated with lung adenocarcinoma metastasis based on the TCGA database. Oncol Rep. 2016;35(4):2257–69. https://doi.org/10.3892/or.2016.4560.
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98. https://doi.org/10.1016/j.ccr.2006.01.025.
Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011;17(7):1875–82. https://doi.org/10.1158/1078-0432.CCR-10-2961.
Boeri M, Pastorino U, Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 2012;18(3):268–74. https://doi.org/10.1097/PPO.0b013e318258b743.
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68(20):8535–40. https://doi.org/10.1158/0008-5472.CAN-08-2129.
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104(40):15805–10. https://doi.org/10.1073/pnas.0707628104.
Jana S, Krishna M, Singhal J, Horne D, Awasthi S, Salgia R, et al. Therapeutic targeting of miRNA-216b in cancer. Cancer Lett. 2020;484:16–28. https://doi.org/10.1016/j.canlet.2020.04.020.
Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, et al. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci. 2011;124(17):2997–3005. https://doi.org/10.1242/jcs.085050.
Menbari MN, Rahimi K, Ahmadi A, Elyasi A, Darvishi N, Hosseini V, et al. MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression. Life Sci. 2019;237:116945. https://doi.org/10.1016/j.lfs.2019.116945.
Wu X, Chen W, Cai H, Hu J, Wu B, Jiang Y, et al. MiR-216b inhibits pancreatic cancer cell progression and promotes apoptosis by down-regulating KRAS. Arch Med Sci. 2018;14(6):1321–32. https://doi.org/10.5114/aoms.2018.72564.
Cai X, Xiao W, Shen J, et al. Thiostrepton and miR-216b synergistically promote osteosarcoma cell cytotoxicity and apoptosis by targeting FoxM1. Oncol Lett. 2020;20:391.
Wang L, Wang Y, Du X, et al. MiR-216b suppresses cell proliferation, migration, invasion, and epithelial-mesenchymal transition by regulating FOXM1 expression in human non-small cell lung cancer. Onco Targets Ther. 2019;12:2999–3009. https://doi.org/10.2147/OTT.S202523.
Zhang T, Ma G, Zhang Y, Huo H, Zhao Y. miR-216b inhibits glioma cell migration and invasion through suppression of FoxM1. Oncol Rep. 2017;38(3):1751–9. https://doi.org/10.3892/or.2017.5824.
He S, Liao B, Deng Y, Su C, Tuo J, Liu J, et al. MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis. BMC Cancer. 2017;17(1):673. https://doi.org/10.1186/s12885-017-3650-5.
Sun M, Wang X, Tu C, Wang S, Qu J, Xiao S. microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo. Cell Biol Int. 2017;41(12):1272–82. https://doi.org/10.1002/cbin.10754.
Zheng WW, Zhou J, Zhang CH, Liu XS. MicroRNA-216b is downregulated in hepatocellular carcinoma and inhibits HepG2 cell growth by targeting Forkhead box protein M1. Eur Rev Med Pharmacol Sci. 2016;20(12):2541–50.
Vu T, Yang S, Datta PK. MiR-216b/Smad3/BCL-2 axis is involved in smoking-mediated drug resistance in non-small cell lung cancer. Cancers (Basel). 2020;12:1879.
Chai Y, Xue H, Wu Y, du X, Zhang Z, Zhang Y, et al. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase. Exp Ther Med. 2018;15(6):4822–8. https://doi.org/10.3892/etm.2018.6020.
Chen L, Han X, Hu Z, Chen L. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis. Cancer Chemother Pharmacol. 2019;83(5):921–31. https://doi.org/10.1007/s00280-019-03808-3.
Huang J, Lin C, Dong H, Piao Z, Jin C, Han H, et al. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1. Cancer Chemother Pharmacol. 2020;86(5):663–72. https://doi.org/10.1007/s00280-020-04152-7.
Huang G, Pan J, Ye Z, Fang B, Cheng W, Cao Z. Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget. 2017;8(61):104206–15. https://doi.org/10.18632/oncotarget.22171.
Liu W, Liu J, Zhang Q, Wei L. Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer. Cancer Biomark. 2020;27(1):113–20. https://doi.org/10.3233/CBM-190914.
Panda M, Tripathi SK, Biswal BK. SOX9: an emerging driving factor from cancer progression to drug resistance. Biochim Biophys Acta Rev Cancer. 1875;2021:188517.
Johannes L, Lucchino M. Current challenges in delivery and cytosolic translocation of therapeutic RNAs. Nucleic Acid Ther. 2018;28(3):178–93. https://doi.org/10.1089/nat.2017.0716.